Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions

AdebrelimabEsophageal CancerPerioperative Period

Interventions

DRUG

adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil

adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；

Trial Locations (1)

The First Affiliated Hospital, the Air Force Medical University, Xi'an

All Listed Sponsors

lead

Xijing Hospital

OTHER

NCT06198465 - Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma | Biotech Hunter | Biotech Hunter